YMTX

Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer...

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced t...

-SEC Filing

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)

Shares of Yumanity to commence trading on Nasdaq under new ticker symbol "YMTX" on December 23, 2020

Proteostasis Therapeutics ([[PTI]]) and Yumanity Therapeutics have completed its reverse merger.The combined company will operate under the name Yumanity Therapeutics and its shares will commence trading on the Nasdaq Capital Market on December 23,

Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis

, /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at on (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated , as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned subsidiary of Proteostasis ("Merger Sub") (the "Merger Agreement"), including (i) the issuance of Proteostasis common stock in the Merger in accordance with the terms of the Merger Agreement; (ii) a reverse stock split of Proteostasis common stock, at a ratio of one new share for every 20 to 30 shares outstanding, with the exact ratio and effective time of the reverse stock split to be determined by the Proteostasis board of directors and publicly announced by press release; and (iii) an amendment to the Proteostasis certificate of incorporation to effect the change of name from "Proteostasis Therapeutics, Inc." to "Yumanity Therapeutics, Inc." Also approved was the compensation that will or may become payable by Proteostasis to its named executive officers in connection with the Merger, on a non-binding advisory vote basis.